½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1300791

¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : °¨¿° À¯Çüº°, Áø´Üº°, Ä¡·áº°, Åõ¿© °æ·Îº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Perinatal Infections Market Size Study & Forecast, by Infection Type, By Diagnosis, By Treatment, By Route of Administration, By End-user, and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÁÖ»ê±â °¨¿°Àº ÀӽŠÁß ¶Ç´Â ºÐ¸¸ Á÷ÈÄ¿¡ ¹ß»ýÇÏ´Â °¨¿°À¸·Î ¸ðü¿¡¼­ žƳª ½Å»ý¾Æ¿¡°Ô Àü¿°µÉ ¼ö ÀÖ´Â °¨¿°À» ¸»ÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ °¨¿°Àº ÀϹÝÀûÀ¸·Î ¹ÚÅ׸®¾Æ, ¹ÙÀÌ·¯½º, °õÆÎÀÌ, ±â»ýÃæ¿¡ ÀÇÇØ ¹ß»ýÇÏ¸ç »ê¸ð¿Í ÅÂ¾Æ ¸ðµÎ¿¡°Ô ½É°¢ÇÑ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀϹÝÀûÀÎ ÁÖ»ê±â °¨¿°¿¡´Â °Å´ë ¼¼Æ÷ ¹ÙÀÌ·¯½º °¨¿°, Àå ¹ÙÀÌ·¯½º °¨¿°, »ý½Ä±â Æ÷Áø, ÀÓÁú, Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º µîÀÌ ÀÖ½À´Ï´Ù. ÁÖ»ê±â °¨¿° ȯÀÚÀÇ ±ÞÁõ, Ä¡·á °¡´É¼º¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Á¤ºÎ À̴ϼÅƼºê Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÇöÀå °Ë»ç¿¡ ´ëÇÑ Ãß¼¼ Áõ°¡´Â ¼¼°è ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÏ´Â °¡Àå µÎµå·¯Áø ¿äÀÎÀÔ´Ï´Ù.

¶ÇÇÑ, Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV) À¯º´·ü Áõ°¡´Â ¼¼°è ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, HIV¿¡ °¨¿°µÈ ÀÓ»êºÎ´Â ¹ÙÀÌ·¯½º ¸ð¼º °¨¿° À§ÇèÀ» ÁÙÀ̱â À§ÇØ Ç×·¹Æ®·Î¹ÙÀÌ·¯½º Ä¡·á(ART)¸¦ ÇÊ¿ä·Î ÇÕ´Ï´Ù. HIV.gov¿¡ µû¸£¸é 2021³â¿¡´Â ¼¼°èÀûÀ¸·Î ¾à 3,840¸¸ ¸íÀÌ HIV¿¡ °¨¿°µÆÀ¸¸ç, ÀÌ Áß 170¸¸ ¸íÀº ¼Ò¾Æ(15¼¼ ¹Ì¸¸), 3,670¸¸ ¸íÀº ¼ºÀÎÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼ºÀÎÀÎ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ, 2021³â¿¡´Â ¼¼°èÀûÀ¸·Î ¾à 150¸¸ ¸íÀÌ HIV¿¡ °¨¿°µÇ¾ú½À´Ï´Ù. ÀÌ¿¡ µû¶ó HIV ¿¹¹æ ¹× Ä¡·á¿¡ ´ëÇÑ Àνİú ³ë·ÂÀÌ ³ô¾ÆÁ³°í, ARTÀÇ °¡¿ë¼ºÀº ÁÖ»ê±â HIV °¨¿° °¡´É¼ºÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ¾î ¼¼°è ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ ¼Ò¸Å ¾à±¹¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Áø´Ü Å×½ºÆ®ÀÇ ±â¼ú ¹ßÀüÀº ÇâÈÄ ¸î ³âµ¿¾È ´Ù¾çÇÑ ¼öÀÍ ±âȸ¸¦ Á¦°øÇÒ °ÍÀÔ´Ï´Ù. ±×·¯³ª ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·°ú ³ôÀº Ä¡·á ºñ¿ëÀ¸·Î ÀÎÇØ 2023-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼¼°è ÁÖ»ê±â °¨¿° ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µîÀÔ´Ï´Ù. ºÏ¹Ì´Â Áø·á ½ÃÁ¡ °Ë»ç¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, Á¤ºÎ À̴ϼÅƼºê Áõ°¡, °³ÀÎÈ­ µÈ ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ 2022³â½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÁÖ»ê±â °¨¿°ÀÇ ±ÞÁõ, Ä¡·á °¡´É¼º¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼Ò¸Å ¾à±¹ ¼ö¿ä Áõ°¡, ÀÇ·á ÁöÃâ Áõ°¡´Â ÀÌ Áö¿ª Àüü ½ÃÀå ¼ö¿ä¸¦ Å©°Ô ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù.

ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³âµ¿¾È ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆľÇÇÏ°í ÇâÈÄ ¸î ³âµ¿¾È ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ »ê¾÷ÀÇ ÁúÀû/¾çÀû Ãø¸éÀ» Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇöȲ
  • ¼¼°è ½ÃÀ塤ºÎ¹®º° ½ÃÀå Ã߻ꡤ¿¹Ãø, 2020-2030³â
    • ÁÖ»ê±â °¨¿° ½ÃÀå : Áö¿ªº°, 2020-2030³â
    • ÁÖ»ê±â °¨¿° ½ÃÀå : °¨¿° À¯Çüº°, 2020-2030³â
    • ÁÖ»ê±â °¨¿° ½ÃÀå : Áø´Üº°, 2020-2030³â
    • ÁÖ»ê±â °¨¿° ½ÃÀå : Ä¡·áº°, 2020-2030³â
    • ÁÖ»ê±â °¨¿° ½ÃÀå : Åõ¿© °æ·Îº°, 2020-2030³â
    • ÁÖ»ê±â °¨¿° ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2030³â
  • ÁÖ¿ä µ¿Çâ
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ÀüÁ¦Á¶°Ç

Á¦2Àå ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • »ê¾÷ ¹ßÀü
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³âµµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå ¿ªÇÐ

  • ÁÖ»ê±â °¨¿° ½ÃÀå¿¡ ´ëÇÑ ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ½ÃÀå ±âȸ

Á¦4Àå ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19ÀÇ ¿µÇ⠺м®
  • Æı«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦5Àå ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : °¨¿° À¯Çüº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : °¨¿° À¯Çüº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : °¨¿° À¯Çüº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ÁÖ»ê±â °¨¿° ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • °Å´ë¼¼Æ÷¹ÙÀÌ·¯½º °¨¿°
    • ¿£Å׷ιÙÀÌ·¯½º °¨¿°
    • »ý½Ä±â Ç츣Æ佺
    • ÀÓÁú
    • Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º
    • ±âŸ

Á¦6Àå ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Áø´Üº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Áø´Üº°, ½ÇÀû, °¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Áø´Üº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ÁÖ»ê±â °¨¿° ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¸ð¼º °Ë»ç
    • ½Å»ý¾Æ °Ë»ç
    • ±âŸ

Á¦7Àå ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Ä¡·áº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Ä¡·áº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Ä¡·áº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ÁÖ»ê±â °¨¿° ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • Ç×»ýÁ¦
    • Ç×¹ÙÀÌ·¯½ºÁ¦
    • Ç×·¹Æ®·Î¹ÙÀÌ·¯½ºÁ¦
    • ±âŸ

Á¦8Àå ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Åõ¿© °æ·Îº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Åõ¿© °æ·Îº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Åõ¿© °æ·Îº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ÁÖ»ê±â °¨¿° ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • °æ±¸
    • ºñ°æ±¸
    • ±âŸ

Á¦9Àå ÁÖ»ê±â °¨¿° ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ÁÖ»ê±â °¨¿° ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • º´¿ø
    • ÀçÅÃÄ¡·á
    • Àü¹® Ŭ¸®´Ð

Á¦10Àå ¼¼°èÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå : Áö¿ªº° ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • ÁÖ»ê±â °¨¿° ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • °¨¿° À¯Çüº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Áø´Üº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Ä¡·áº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Åõ¿© °æ·Îº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ÃÖÁ¾»ç¿ëÀÚº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÁÖ»ê±â °¨¿° ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Merck KGaA(Germany)
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Beckman Coulter Inc.(U.S.)
    • BIOMERIEUX(France)
    • Bio-Rad Laboratories, Inc(U.S.)
    • Danaher(U.S.)
    • Hologic Inc.(U.S.)
    • Gilead Sciences, Inc.(U.S.)
    • Emcure Pharmaceuticals Limited.(India)
    • Cipla Inc.(U.S.)
    • Johnson & Johnson Private Limited(U.S.)

Á¦12Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç ÀüÁ¦Á¶°Ç
LSH 23.07.31

Global Perinatal Infections Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Perinatal infections are infections that occur during pregnancy or shortly after delivery, which can be transmitted from the mother to the fetus or newborn. These infections is generally caused by bacteria, viruses, fungi, or parasites that exhibit a serious impact on both the mother and the infant. Several common perinatal infections include cytomegalovirus infection, enterovirus infection, genital herpes, gonorrhea, human immunodeficiency virus, others. The surging cases of perinatal infections, growing awareness regarding treatment availability, rising number of government initiatives, spurring demand for personalized medicine, rising inclination towards point-of-care testing are the most prominent factors that are propelling the market demand across the globe.

In addition, the rising incidences of Human Immunodeficiency Virus (HIV) are exhibiting a positive influence on market growth across the globe. Pregnant women with HIV require antiretroviral therapy (ART) to reduce the risk of mother-to-child transmission of the virus. Without proper treatment, the risk of transmission is high and leads to perinatal HIV infection, which can have serious health consequences for the newborn. According to HIV.gov, in 2021it was estimated that nearly 38.4 million people worldwide are suffering from HIV, of which 1.7 million were children (<15 years old) and 36.7 million were adults. Also, in 2021, approximately 1.5 million individuals around the globe acquired HIV. Thereby, the growing awareness and initiatives for HIV prevention and treatment, along with the availability of ART is aids in lessening the chances of perinatal HIV infection, which, in turn, accelerates the global market growth. Moreover, the growing demand for retail pharmacies, as well as the increasing technological advancements in diagnostic tests presents various lucrative opportunities over the forecasting years. However, the lack of skilled professionals and high cost involved in treatment are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Perinatal Infections Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing preference towards point-of-care testing, rising number of government initiatives, and spurring demand for personalized medicine. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The surging cases of perinatal infections, growing awareness regarding treatment availability, increasing demand for retail pharmacies, and rising healthcare spending are significantly propelling the market demand across the region.

Major market players included in this report are:

  • Merck KGaA (Germany)
  • Beckman Coulter Inc. (U.S.)
  • BIOMERIEUX (France)
  • Bio-Rad Laboratories, Inc (U.S.)
  • Danaher (U.S.)
  • Hologic Inc. (U.S.)
  • Gilead Sciences, Inc. (U.S.)
  • Emcure Pharmaceuticals Limited. (India)
  • Cipla Inc. (U.S.)
  • Johnson & Johnson Private Limited (U.S.)

Recent Developments in the Market:

  • In October 2021, Gilead Sciences, Inc. unveiled that the Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) has received U.S. Food and Drug Administration (FDA) approval for a new low-dose tablet dosage form for children and adolescents that are virologically suppressed or new to antiretroviral therapy and weigh between 14 kg and 25 kg. By approving this supplemental New Drug Application (sNDA), Biktarvy's indication has been extended to encompass younger children who are HIV-infected, bridging the gap between paediatric and adult HIV treatment alternatives.

Global Perinatal Infections Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Infection Type, Diagnosis, Treatment, Route of Administration, End-user, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Infection Type:

  • Cytomegalovirus Infection
  • Enterovirus Infection
  • Genital Herpes
  • Gonorrhoea
  • Human Immunodeficiency Virus
  • Others

By Diagnosis:

  • Maternal Test
  • Neonatal Test
  • Others

By Treatment:

  • Antibiotics
  • Antiviral
  • Antiretroviral
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By End-user:

  • Hospitals
  • Homecare
  • Specialty Clinics

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Perinatal Infections Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Perinatal Infections Market, by Infection Type, 2020-2030 (USD Billion)
    • 1.2.3. Perinatal Infections Market, by Diagnosis, 2020-2030 (USD Billion)
    • 1.2.4. Perinatal Infections Market, by Treatment, 2020-2030 (USD Billion)
    • 1.2.5. Perinatal Infections Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.6. Perinatal Infections Market, by End-user, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Perinatal Infections Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Perinatal Infections Market Dynamics

  • 3.1. Perinatal Infections Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Surging cases of perinatal infections
      • 3.1.1.2. Rising incidences of Human Immunodeficiency Virus (HIV)
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lack of skilled professionals
      • 3.1.2.2. High cost involved in the treatment
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing demand for retail pharmacies
      • 3.1.3.2. Increasing technological advancements in diagnostic tests

Chapter 4. Global Perinatal Infections Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Perinatal Infections Market, by Infection Type

  • 5.1. Market Snapshot
  • 5.2. Global Perinatal Infections Market by Infection Type, Performance - Potential Analysis
  • 5.3. Global Perinatal Infections Market Estimates & Forecasts by Infection Type 2020-2030 (USD Billion)
  • 5.4. Perinatal Infections Market, Sub Segment Analysis
    • 5.4.1. Cytomegalovirus Infection
    • 5.4.2. Enterovirus Infection
    • 5.4.3. Genital Herpes
    • 5.4.4. Gonorrhoea
    • 5.4.5. Human Immunodeficiency Virus
    • 5.4.6. Others

Chapter 6. Global Perinatal Infections Market, by Diagnosis

  • 6.1. Market Snapshot
  • 6.2. Global Perinatal Infections Market by Diagnosis, Performance - Potential Analysis
  • 6.3. Global Perinatal Infections Market Estimates & Forecasts by Diagnosis 2020-2030 (USD Billion)
  • 6.4. Perinatal Infections Market, Sub Segment Analysis
    • 6.4.1. Maternal Test
    • 6.4.2. Neonatal Test
    • 6.4.3. Others

Chapter 7. Global Perinatal Infections Market, by Treatment

  • 7.1. Market Snapshot
  • 7.2. Global Perinatal Infections Market by Treatment, Performance - Potential Analysis
  • 7.3. Global Perinatal Infections Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
  • 7.4. Perinatal Infections Market, Sub Segment Analysis
    • 7.4.1. Antibiotics
    • 7.4.2. Antiviral
    • 7.4.3. Antiretroviral
    • 7.4.4. Others

Chapter 8. Global Perinatal Infections Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Perinatal Infections Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Perinatal Infections Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 8.4. Perinatal Infections Market, Sub Segment Analysis
    • 8.4.1. Oral
    • 8.4.2. Parenteral
    • 8.4.3. Others

Chapter 9. Perinatal Infections Market, by End-user

  • 9.1. Market Snapshot
  • 9.2. Global Perinatal Infections Market by End-user, Performance - Potential Analysis
  • 9.3. Global Perinatal Infections Market Estimates & Forecasts by End-user 2020-2030 (USD Billion)
  • 9.4. Perinatal Infections Market, Sub Segment Analysis
    • 9.4.1. Hospitals
    • 9.4.2. Homecare
    • 9.4.3. Specialty Clinics

Chapter 10. Global Perinatal Infections Market, Regional Analysis

  • 10.1. Top Leading Countries
  • 10.2. Top Emerging Countries
  • 10.3. Perinatal Infections Market, Regional Market Snapshot
  • 10.4. North America Perinatal Infections Market
    • 10.4.1. U.S. Perinatal Infections Market
      • 10.4.1.1. Infection Type breakdown estimates & forecasts, 2020-2030
      • 10.4.1.2. Diagnosis breakdown estimates & forecasts, 2020-2030
      • 10.4.1.3. Treatment breakdown estimates & forecasts, 2020-2030
      • 10.4.1.4. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 10.4.1.5. End-user breakdown estimates & forecasts, 2020-2030
    • 10.4.2. Canada Perinatal Infections Market
  • 10.5. Europe Perinatal Infections Market Snapshot
    • 10.5.1. U.K. Perinatal Infections Market
    • 10.5.2. Germany Perinatal Infections Market
    • 10.5.3. France Perinatal Infections Market
    • 10.5.4. Spain Perinatal Infections Market
    • 10.5.5. Italy Perinatal Infections Market
    • 10.5.6. Rest of Europe Perinatal Infections Market
  • 10.6. Asia-Pacific Perinatal Infections Market Snapshot
    • 10.6.1. China Perinatal Infections Market
    • 10.6.2. India Perinatal Infections Market
    • 10.6.3. Japan Perinatal Infections Market
    • 10.6.4. Australia Perinatal Infections Market
    • 10.6.5. South Korea Perinatal Infections Market
    • 10.6.6. Rest of Asia Pacific Perinatal Infections Market
  • 10.7. Latin America Perinatal Infections Market Snapshot
    • 10.7.1. Brazil Perinatal Infections Market
    • 10.7.2. Mexico Perinatal Infections Market
  • 10.8. Middle East & Africa Perinatal Infections Market
    • 10.8.1. Saudi Arabia Perinatal Infections Market
    • 10.8.2. South Africa Perinatal Infections Market
    • 10.8.3. Rest of Middle East & Africa Perinatal Infections Market

Chapter 11. Competitive Intelligence

  • 11.1. Key Company SWOT Analysis
    • 11.1.1. Company 1
    • 11.1.2. Company 2
    • 11.1.3. Company 3
  • 11.2. Top Market Strategies
  • 11.3. Company Profiles
    • 11.3.1. Merck KGaA (Germany)
      • 11.3.1.1. Key Information
      • 11.3.1.2. Overview
      • 11.3.1.3. Financial (Subject to Data Availability)
      • 11.3.1.4. Product Summary
      • 11.3.1.5. Recent Developments
    • 11.3.2. Beckman Coulter Inc. (U.S.)
    • 11.3.3. BIOMERIEUX (France)
    • 11.3.4. Bio-Rad Laboratories, Inc (U.S.)
    • 11.3.5. Danaher (U.S.)
    • 11.3.6. Hologic Inc. (U.S.)
    • 11.3.7. Gilead Sciences, Inc. (U.S.)
    • 11.3.8. Emcure Pharmaceuticals Limited. (India)
    • 11.3.9. Cipla Inc. (U.S.)
    • 11.3.10. Johnson & Johnson Private Limited (U.S.)

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦